Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

ADAM8 in invasive cancers: links to tumor progression, metastasis, and chemoresistance.

Conrad C, Benzel J, Dorzweiler K, Cook L, Schlomann U, Zarbock A, Slater EP, Nimsky C, Bartsch JW.

Clin Sci (Lond). 2019 Jan 11;133(1):83-99. doi: 10.1042/CS20180906. Print 2019 Jan 15. Review.

PMID:
30635388
2.

Chemoprevention with Somatuline© Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1).

Lopez CL, Joos B, Bartsch DK, Manoharan J, Albers M, Slater EP, Bollmann C, Roth S, Bayer A, Fendrich V.

World J Surg. 2019 Mar;43(3):831-838. doi: 10.1007/s00268-018-4839-8.

PMID:
30600364
3.

German National Case Collection for familial pancreatic Cancer (FaPaCa) - acceptance and psychological aspects of a pancreatic cancer screening program.

Franke FS, Matthäi E, Slater EP, Schicker C, Kruse J, Bartsch DK.

Hered Cancer Clin Pract. 2018 Nov 29;16:17. doi: 10.1186/s13053-018-0100-6. eCollection 2018.

4.

The Combination of MiRNA-196b, LCN2, and TIMP1 is a Potential Set of Circulating Biomarkers for Screening Individuals at Risk for Familial Pancreatic Cancer.

Bartsch DK, Gercke N, Strauch K, Wieboldt R, Matthäi E, Wagner V, Rospleszcz S, Schäfer A, Franke FS, Mintziras I, Bauer C, Grote T, Figiel J, Di Fazio P, Burchert A, Reinartz S, Pogge von Strandmann E, Klöppel G, Slater EP.

J Clin Med. 2018 Sep 20;7(10). pii: E295. doi: 10.3390/jcm7100295.

5.

Chemoprevention with Enalapril and Aspirin in Men1(+/T) Knockout Mouse Model.

Manoharan J, Fendrich V, Di Fazio P, Bollmann C, Roth S, Joos B, Mintziras I, Albers MB, Ramaswamy A, Bertolino P, Zhang CX, Slater EP, Bartsch DK, Lopez-Lopez CL.

Neuroendocrinology. 2018;107(3):257-266. doi: 10.1159/000492224. Epub 2018 Jul 19.

PMID:
30025403
6.

Genetic and pharmacologic abrogation of Snail1 inhibits acinar-to-ductal metaplasia in precursor lesions of pancreatic ductal adenocarcinoma and pancreatic injury.

Fendrich V, Jendryschek F, Beeck S, Albers M, Lauth M, Esni F, Heeger K, Dengler J, Slater EP, Holler JPN, Baier A, Bartsch DK, Waldmann J.

Oncogene. 2018 Apr;37(14):1845-1856. doi: 10.1038/s41388-017-0100-4. Epub 2018 Jan 25.

PMID:
29367759
7.

Overexpression of MicroRNA miR-7-5p Is a Potential Biomarker in Neuroendocrine Neoplasms of the Small Intestine.

Heverhagen AE, Legrand N, Wagner V, Fendrich V, Bartsch DK, Slater EP.

Neuroendocrinology. 2018;106(4):312-317. doi: 10.1159/000480121. Epub 2017 Aug 19.

PMID:
28848144
8.

Is Routine Screening of Young Asymptomatic MEN1 Patients Necessary?

Manoharan J, Raue F, Lopez CL, Albers MB, Bollmann C, Fendrich V, Slater EP, Bartsch DK.

World J Surg. 2017 Aug;41(8):2026-2032. doi: 10.1007/s00268-017-3992-9.

PMID:
28321559
9.

Limited Value of Ga-68-DOTATOC-PET-CT in Routine Screening of Patients with Multiple Endocrine Neoplasia Type 1.

Albers MB, Librizzi D, Lopez CL, Manoharan J, Apitzsch JC, Slater EP, Bollmann C, Kann PH, Bartsch DK.

World J Surg. 2017 Jun;41(6):1521-1527. doi: 10.1007/s00268-017-3907-9.

PMID:
28138732
10.

Double germline mutations in APC and BRCA2 in an individual with a pancreatic tumor.

Goehringer C, Sutter C, Kloor M, Gebert J, Slater EP, Keller M, Treiber I, Ganschow P, Kadmon M, Moog U.

Fam Cancer. 2017 Apr;16(2):303-309. doi: 10.1007/s10689-016-9952-y.

PMID:
27838800
11.

Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.

Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthäi E, Carrato A, Earl J, Robbers K, van Mil AM, Potjer T, Bonsing BA, de Vos Tot Nederveen Cappel WH, Bergman W, Wasser M, Morreau H, Klöppel G, Schicker C, Steinkamp M, Figiel J, Esposito I, Mocci E, Vazquez-Sequeiros E, Sanjuanbenito A, Muñoz-Beltran M, Montans J, Langer P, Fendrich V, Bartsch DK.

J Clin Oncol. 2016 Jun 10;34(17):2010-9. doi: 10.1200/JCO.2015.64.0730. Epub 2016 Apr 25.

PMID:
27114589
12.

An unusual phenotype of MEN1 syndrome with a SI-NEN associated with a deletion of the MEN1 gene.

Manoharan J, Lopez CL, Hackmann K, Albers MB, Pehl A, Kann PH, Slater EP, Schröck E, Bartsch DK.

Endocrinol Diabetes Metab Case Rep. 2016;2016:160011. doi: 10.1530/EDM-16-0011. Epub 2016 Mar 2.

13.

Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer.

Di Fazio P, Waldegger P, Jabari S, Lingelbach S, Montalbano R, Ocker M, Slater EP, Bartsch DK, Illig R, Neureiter D, Wissniowski TT.

Oncotarget. 2016 May 17;7(20):28998-9010. doi: 10.18632/oncotarget.8585.

14.

Bronchopulmonary Neuroendocrine Neoplasms and Their Precursor Lesions in Multiple Endocrine Neoplasia Type 1.

Bartsch DK, Albers MB, Lopez CL, Apitzsch JC, Walthers EM, Fink L, Fendrich V, Slater EP, Waldmann J, Anlauf M.

Neuroendocrinology. 2016;103(3-4):240-7. doi: 10.1159/000435921. Epub 2015 Jun 18.

PMID:
26113081
15.

Frequency and clinical correlates of somatic Ying Yang 1 mutations in sporadic insulinomas.

Lichtenauer UD, Di Dalmazi G, Slater EP, Wieland T, Kuebart A, Schmittfull A, Schwarzmayr T, Diener S, Wiese D, Thasler WE, Reincke M, Meitinger T, Schott M, Fassnacht M, Bartsch DK, Strom TM, Beuschlein F.

J Clin Endocrinol Metab. 2015 May;100(5):E776-82. doi: 10.1210/jc.2015-1100. Epub 2015 Mar 12.

PMID:
25763608
16.

IGF-1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells.

Münzberg C, Höhn K, Krndija D, Maaß U, Bartsch DK, Slater EP, Oswald F, Walther P, Seufferlein T, von Wichert G.

J Cell Mol Med. 2015 May;19(5):948-59. doi: 10.1111/jcmm.12473. Epub 2015 Mar 8.

17.

Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain.

Bartsch DK, Slater EP, Albers M, Knoop R, Chaloupka B, Lopez CL, Fendrich V, Kann PH, Waldmann J.

J Clin Endocrinol Metab. 2014 Nov;99(11):E2387-91. doi: 10.1210/jc.2013-4432. Epub 2014 Sep 11.

PMID:
25210877
18.

MicroRNA-196a and -196b as Potential Biomarkers for the Early Detection of Familial Pancreatic Cancer.

Slater EP, Strauch K, Rospleszcz S, Ramaswamy A, Esposito I, Klöppel G, Matthäi E, Heeger K, Fendrich V, Langer P, Bartsch DK.

Transl Oncol. 2014 Aug;7(4):464-71. doi: 10.1016/j.tranon.2014.05.007. Epub 2014 Jun 21.

19.

LCN2 and TIMP1 as Potential Serum Markers for the Early Detection of Familial Pancreatic Cancer.

Slater EP, Fendrich V, Strauch K, Rospleszcz S, Ramaswamy A, Mätthai E, Chaloupka B, Gress TM, Langer P, Bartsch DK.

Transl Oncol. 2013 Apr;6(2):99-103. Epub 2013 Apr 1.

20.

Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors.

Fendrich V, Maschuw K, Rehm J, Buchholz M, Holler JP, Slater EP, Bartsch DK, Waldmann J.

ScientificWorldJournal. 2012;2012:529151. doi: 10.1100/2012/529151. Epub 2012 Dec 27.

Supplemental Content

Loading ...
Support Center